Unlike traditional medications such as disulfiram, naltrexone, and buprenorphine, which primarily target neurotransmitter pathways directly associated with addiction, GLP-1RAs modulate reward mechanisms indirectly through metabolic and neuroendocrine pathways
By starting slowly and incorporating one therapy at a time, a patient can discontinue a therapy quickly if it causes intolerable negative impacts
they are not FDA-approved as finished products
If GI side effects are manageable, add cagrilintide at 0.25 mg weekly starting in week 5, while simultaneously increasing retatrutide to 2 mg as per its standard titration
The results are presented in the Table 4
Conversely, estrogen stimulation enhanced cystine uptake (Fig